These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33676870)

  • 1. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
    Wan X; Zhang Y; Ma J; Tan C; Zeng X; Peng L
    Breast; 2019 Feb; 43():1-6. PubMed ID: 30342258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
    Loke L; Lee SC; Pearce F; Ng K; Aziz MIA
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1308. PubMed ID: 33085843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
    Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
    Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
    Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
    BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
    Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.
    Jiang W; He Z; Zhang T; Guo C; Zhao J; Zhu J; Wu J; Yu X; Chen C; Li J; Jiang J
    Immunotherapy; 2021 Jun; 13(8):661-668. PubMed ID: 33876668
    [No Abstract]   [Full Text] [Related]  

  • 14. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
    Bardia A; Su F; Solovieff N; Im SA; Sohn J; Lee KS; Campos-Gomez S; Jung KH; Colleoni M; Vázquez RV; Franke F; Hurvitz S; Harbeck N; Chow L; Taran T; Rodriguez Lorenc K; Babbar N; Tripathy D; Lu YS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34504990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.
    Jeong E; Wang C; Wilson L; Zhong L
    Front Oncol; 2021; 11():658054. PubMed ID: 34026637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
    Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
    Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.